NCT00698945View on ClinicalTrials.gov

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Ocular HypertensionOpen-Angle Glaucoma
Interventions
DRUG

Istalol and Optive

Istalol: one drop a day for 28 days Optive: one drop a day for 28 days

DRUG

Alphagan

Alphagan: two drops a day for 28 days

Trial Locations (1)

94954

North Bay Eye Associates, Inc., Petaluma

Sponsors

Lead Sponsor

Bp Consulting, Inc
All Listed Sponsors
lead

Bp Consulting, Inc

NETWORK

NCT00698945 - Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) | Biotech Hunter | Biotech Hunter